Home > Publications database > Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors. > print |
001 | 130418 | ||
005 | 20240228143431.0 | ||
024 | 7 | _ | |a 10.1007/s00401-016-1549-x |2 doi |
024 | 7 | _ | |a pmid:26920151 |2 pmid |
024 | 7 | _ | |a pmc:PMC5039033 |2 pmc |
024 | 7 | _ | |a 0001-6322 |2 ISSN |
024 | 7 | _ | |a 1432-0533 |2 ISSN |
024 | 7 | _ | |a altmetric:6015717 |2 altmetric |
037 | _ | _ | |a DKFZ-2017-05497 |
041 | _ | _ | |a eng |
082 | _ | _ | |a 610 |
100 | 1 | _ | |a Rivera, Barbara |b 0 |
245 | _ | _ | |a Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors. |
260 | _ | _ | |a Berlin |c 2016 |b Springer |
336 | 7 | _ | |a article |2 DRIVER |
336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1522138933_18537 |2 PUB:(DE-HGF) |
336 | 7 | _ | |a ARTICLE |2 BibTeX |
336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
520 | _ | _ | |a Dysembryoplastic neuroepithelial tumor (DNET) is a benign brain tumor associated with intractable drug-resistant epilepsy. In order to identify underlying genetic alterations and molecular mechanisms, we examined three family members affected by multinodular DNETs as well as 100 sporadic tumors from 96 patients, which had been referred to us as DNETs. We performed whole-exome sequencing on 46 tumors and targeted sequencing for hotspot FGFR1 mutations and BRAF p.V600E was used on the remaining samples. FISH, copy number variation assays and Sanger sequencing were used to validate the findings. By whole-exome sequencing of the familial cases, we identified a novel germline FGFR1 mutation, p.R661P. Somatic activating FGFR1 mutations (p.N546K or p.K656E) were observed in the tumor samples and further evidence for functional relevance was obtained by in silico modeling. The FGFR1 p.K656E mutation was confirmed to be in cis with the germline p.R661P variant. In 43 sporadic cases, in which the diagnosis of DNET could be confirmed on central blinded neuropathology review, FGFR1 alterations were also frequent and mainly comprised intragenic tyrosine kinase FGFR1 duplication and multiple mutants in cis (25/43; 58.1 %) while BRAF p.V600E alterations were absent (0/43). In contrast, in 53 cases, in which the diagnosis of DNET was not confirmed, FGFR1 alterations were less common (10/53; 19 %; p < 0.0001) and hotspot BRAF p.V600E (12/53; 22.6 %) (p < 0.001) prevailed. We observed overexpression of phospho-ERK in FGFR1 p.R661P and p.N546K mutant expressing HEK293 cells as well as FGFR1 mutated tumor samples, supporting enhanced MAP kinase pathway activation under these conditions. In conclusion, constitutional and somatic FGFR1 alterations and MAP kinase pathway activation are key events in the pathogenesis of DNET. These findings point the way towards existing targeted therapies. |
536 | _ | _ | |a 312 - Functional and structural genomics (POF3-312) |0 G:(DE-HGF)POF3-312 |c POF3-312 |f POF III |x 0 |
588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
650 | _ | 7 | |a FGFR1 protein, human |0 EC 2.7.10.1 |2 NLM Chemicals |
650 | _ | 7 | |a Receptor, Fibroblast Growth Factor, Type 1 |0 EC 2.7.10.1 |2 NLM Chemicals |
650 | _ | 7 | |a Proto-Oncogene Proteins B-raf |0 EC 2.7.11.1 |2 NLM Chemicals |
700 | 1 | _ | |a Gayden, Tenzin |b 1 |
700 | 1 | _ | |a Carrot-Zhang, Jian |b 2 |
700 | 1 | _ | |a Nadaf, Javad |b 3 |
700 | 1 | _ | |a Boshari, Talia |b 4 |
700 | 1 | _ | |a Faury, Damien |b 5 |
700 | 1 | _ | |a Zeinieh, Michele |b 6 |
700 | 1 | _ | |a Blanc, Romeo |b 7 |
700 | 1 | _ | |a Burk, David L |b 8 |
700 | 1 | _ | |a Fahiminiya, Somayyeh |b 9 |
700 | 1 | _ | |a Bareke, Eric |b 10 |
700 | 1 | _ | |a Schüller, Ulrich |b 11 |
700 | 1 | _ | |a Monoranu, Camelia M |b 12 |
700 | 1 | _ | |a Sträter, Ronald |b 13 |
700 | 1 | _ | |a Kerl, Kornelius |b 14 |
700 | 1 | _ | |a Niederstadt, Thomas |b 15 |
700 | 1 | _ | |a Kurlemann, Gerhard |b 16 |
700 | 1 | _ | |a Ellezam, Benjamin |b 17 |
700 | 1 | _ | |a Michalak, Zuzanna |b 18 |
700 | 1 | _ | |a Thom, Maria |b 19 |
700 | 1 | _ | |a Lockhart, Paul J |b 20 |
700 | 1 | _ | |a Leventer, Richard J |b 21 |
700 | 1 | _ | |a Ohm, Milou |b 22 |
700 | 1 | _ | |a MacGregor, Duncan |b 23 |
700 | 1 | _ | |a Jones, David |0 P:(DE-He78)551bb92841f634070997aa168d818492 |b 24 |u dkfz |
700 | 1 | _ | |a Karamchandani, Jason |b 25 |
700 | 1 | _ | |a Greenwood, Celia M T |b 26 |
700 | 1 | _ | |a Berghuis, Albert M |b 27 |
700 | 1 | _ | |a Bens, Susanne |b 28 |
700 | 1 | _ | |a Siebert, Reiner |b 29 |
700 | 1 | _ | |a Zakrzewska, Magdalena |b 30 |
700 | 1 | _ | |a Liberski, Pawel P |b 31 |
700 | 1 | _ | |a Zakrzewski, Krzysztof |b 32 |
700 | 1 | _ | |a Sisodiya, Sanjay M |b 33 |
700 | 1 | _ | |a Paulus, Werner |b 34 |
700 | 1 | _ | |a Albrecht, Steffen |b 35 |
700 | 1 | _ | |a Hasselblatt, Martin |b 36 |
700 | 1 | _ | |a Jabado, Nada |b 37 |
700 | 1 | _ | |a Foulkes, William D |b 38 |
700 | 1 | _ | |a Majewski, Jacek |b 39 |
773 | _ | _ | |a 10.1007/s00401-016-1549-x |g Vol. 131, no. 6, p. 847 - 863 |0 PERI:(DE-600)1458410-4 |n 6 |p 847 - 863 |t Acta neuropathologica |v 131 |y 2016 |x 1432-0533 |
909 | C | O | |o oai:inrepo02.dkfz.de:130418 |p VDB |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 24 |6 P:(DE-He78)551bb92841f634070997aa168d818492 |
913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-312 |2 G:(DE-HGF)POF3-300 |v Functional and structural genomics |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
914 | 1 | _ | |y 2016 |
915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ACTA NEUROPATHOL : 2015 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b ACTA NEUROPATHOL : 2015 |
920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l Pädiatrische Neuroonkologie |x 0 |
920 | 1 | _ | |0 I:(DE-He78)L101-20160331 |k L101 |l DKTK Heidelberg |x 1 |
980 | _ | _ | |a journal |
980 | _ | _ | |a VDB |
980 | _ | _ | |a I:(DE-He78)B062-20160331 |
980 | _ | _ | |a I:(DE-He78)L101-20160331 |
980 | _ | _ | |a UNRESTRICTED |
Library | Collection | CLSMajor | CLSMinor | Language | Author |
---|